Yixing Shen

This inventor holds 15 USPTO granted patents, plus 2 CIPO patents and 4 EPO patents, primarily in Hematopoietic Growth Factors. Top assignee: Ligand Pharmaceuticals, Inc.. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yixing Shen. Retrieved from https://idiyas.com/inventor/yixing-shen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15

% Patents Active = 73.3

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 8.7

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2013)
Encinitas, CA (US) (2010 - 2023)

Company Filing History:

15 out of 140

Ligand Pharmaceuticals, Inc.

patents

Years Active: 2010-2023

Loading Chart...

Areas of Expertise:

Heterocycle Amines

Granulocyte Colony-Stimulating Factor

Hematopoietic Growth Factors

Small Molecule Compounds

Androgen Receptor Modulators

Cycloamino Derivatives

Receptor Activation

Compositions

Methods

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11773110 - Heterocycle amines and uses thereof (2023-10-03),

2. 11413274 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2022-08-16),

3. 11186593 - Heterocycle amines and uses thereof (2021-11-30),

4. 10736875 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2020-08-11),

5. 10604533 - Heterocycle amines and uses thereof (2020-03-31),

6. 10111859 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2018-10-30),

7. 10030034 - Heterocycle amines and uses thereof (2018-07-24),

8. 9622991 - Hematopoietic growth factor mimetic small molecule compounds and their uses (2017-04-18),

9. 9492430 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2016-11-15),

10. 9266874 - Heterocycle amines and uses thereof (2016-02-23),

11. 9144557 - Hematopoietic growth factor mimetic small molecule compounds and their uses (2015-09-29),

12. 8680150 - Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors (2014-03-25),

13. 8580811 - Androgen receptor modulator methods (2013-11-12),

14. 8193357 - Androgen receptor modulator compounds (2012-06-05),

15. 7816372 - 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds (2010-10-19),

Title: Yixing Shen: Innovator in Chemistry and Medicine

Introduction

Yixing Shen is a prominent inventor based in Encinitas, California. He has made significant contributions to the fields of chemistry and medicine, holding a total of 15 patents. His work focuses on developing compounds and methods that address various medical challenges.

Latest Patents

Among his latest patents, Yixing Shen has developed heterocycle amines and their uses. These compounds and methods are particularly relevant in treating inflammatory disorders. Additionally, he has worked on methods and compositions associated with the granulocyte colony-stimulating factor receptor. Some of these embodiments include identifying compounds that modulate the activity of the receptor, which can be beneficial in treating hematopoietic or neurological disorders.

Career Highlights

Yixing Shen is currently employed at Ligand Pharmaceuticals, Inc., where he continues to innovate and contribute to the advancement of medical science. His extensive research and development efforts have positioned him as a key figure in his field.

Collaborations

Throughout his career, Yixing Shen has collaborated with notable colleagues, including Lin Zhi and Bijan Pedram. These partnerships have further enhanced his research and the impact of his inventions.

Conclusion

Yixing Shen's work exemplifies the intersection of innovation and practical application in medicine. His contributions through patents and collaborations continue to influence the field positively.

Profile summary based on public USPTO records.